Mikko Vahteristo

Mikko Vahteristo

Auto-generated profile, based on publicly available information

Mikko Vahteristo

Orion Corporation, Espoo, Finland

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2021 in International Journal of Chronic Obstructive Pulmonary Disease
Verified
Journal Article
Open access
PDF file
RJRain Jõgi
Rain Jõgi
LMLeena Mattila
Leena Mattila
MVMikko Vahteristo
Mikko Vahteristo
ATAino Takala
Aino Takala
SLSatu Lähelmä
Satu Lähelmä
ALAri Lindqvist
Ari Lindqvist
Introduction: Achieving correct inhalation technique through an inhaler to ensure effective drug delivery is key to managing symptoms in patients with chronic obstructive pulmonary disease (COPD). However, many patients struggle to use their inhalers correctly, with the resultant reduction in therapeutic benefit. Consequently, appropriate inhaler choice is important to maximize clinical benefit. The primary objective of this study was to characterize inspiratory flow parameters across two Easyhaler® inhalers and the HandiHaler® inhaler in patients with COPD and healthy volunteers. Methods: In this randomized, open-label, crossover study, subjects (100 patients with COPD; 100 healthy volunteers) were trained to perform inhalations of placebo powder via two variants of Easyhaler and placebo capsules via the HandiHaler inhalers. Subjects then performed three placebo inhalations through each inhaler in a random sequence. Inspiratory flow parameters were assessed, including peak inspiratory flow (PIF), for each inhaler. A parallel sub-study was conducted in patients with COPD from the main study to assess correct use of the inhalers, patient’s preference, ability to learn to use the inhalers, and the feasibility of the In-Check Dial device to measure PIF values. Results: Mean PIF rates and inspiratory volumes through the three inhalers were similar between patients with COPD and healthy volunteers, and all subjects achieved the 30 L/min PIF required for effective use of Easyhaler. Almost 70% of the 88 patients enrolled in the sub-study used the Easyhaler and HandiHaler inhalers without errors. The Easyhaler was preferred by 51% of patients, while 25% favored the HandiHaler. Teaching the use of both inhalers to almost 70% of patients was very easy. The In-Check Dial PIF values and those obtained via spirometry were strongly correlated (p< 0.0001) for all three inhalers. Conclusion: The respiratory performance of patients with COPD does not appear to be a limiting factor in the use of Easyhaler.

1 November 1998 in Environment International
Verified
Journal Article
Closed access
APArto S. Pennanen
Arto S. Pennanen
RSRaimo O. Salonen
Raimo O. Salonen
MVMikko Vahteristo
Mikko Vahteristo
KLKi Young Lee
Ki Young Lee
JSJohn D. Spengler
John D. Spengler

30 October 2022 in European Journal of Drug Metabolism and Pharmacokinetics
Verified
Journal Article
Closed access
PDF file
JTJohanna Maria Tuunainen
Johanna Maria Tuunainen
NSNoora Sjöstedt
Noora Sjöstedt
MVMikko Vahteristo
Mikko Vahteristo
JEJuha Ellmén
Juha Ellmén
MKMikko Kuoppamäki
Mikko Kuoppamäki
MYMarjo Yliperttula
Marjo Yliperttula

6 June 2024 in Respiratory Medicine
Verified
Journal Article
Open access
JKJussi Karjalainen
Jussi Karjalainen
VVVille Vartiainen
Ville Vartiainen
ATAntti Tikkakoski
Antti Tikkakoski
LML. Pekka Malmberg
L. Pekka Malmberg
LVLiisa Vuotari
Liisa Vuotari
LLLauri Lehtimäki
Lauri Lehtimäki
Salbutamol is a cornerstone for relieving acute asthma symptoms, typically administered through a pressurized metered-dose inhaler (pMDI). Dry powder inhalers (DPIs) offer an alternative, but concerns exist whether DPIs provide an effective relief during an obstructive event. We aimed to show non-inferiority of Salbutamol Easyhaler DPI compared to pMDI with spacer in treating methacholine-induced bronchoconstriction. Applicability of Budesonide-formoterol Easyhaler DPI as a reliever was also assessed. This was a randomized, parallel-group trial in subjects sent to methacholine challenge (MC) test for asthma diagnostics. Participants with at least 20% decrease in forced expiratory volume in one second (FEV1) were randomized to receive Salbutamol Easyhaler (2x200 μg), Ventoline Evohaler with spacer (4x100 μg) or Budesonide-formoterol Easyhaler (2x160/4.5 μg) as a reliever. The treatment was repeated if FEV1 did not recover to at least -10% of baseline. 180 participants (69% females, mean age 46 yrs [range 18-80], FEV1%pred 89.5 [62-142] %) completed the trial. Salbutamol Easyhaler was non-inferior to pMDI with spacer in acute relief of bronchoconstriction showing a -0.083 (95% LCL -0.146) L FEV1 difference after the first dose and -0.032 (-0.071) L after the last dose. The differences in FEV1 between Budesonide-formoterol Easyhaler and Salbutamol pMDI with spacer were -0.163 (-0.225) L after the first and -0.092 (-0.131) L after the last dose. The study confirms non-inferiority of Salbutamol Easyhaler to Ventoline Evohaler with spacer in relieving acute bronchoconstriction, making Easyhaler a sustainable and safe reliever for MC test and supports its use during asthma attacks.

19 August 2026 in Parkinsonism & Related Disorders
Verified
Journal Article
Open access
Dag NyholmDag Nyholm
Dag Nyholm
DPDavide Paonessa
Davide Paonessa
Filip BergquistFilip Bergquist
Filip Bergquist
JTJan Erik Timmermann
Jan Erik Timmermann
MVMikko Vahteristo
Mikko Vahteristo
POPer Odin
Per Odin